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INTRODUCTION
I n t r a d u c t a l  p a p i l l a r y 
mucinous neoplasms (IPMNs) of 
the pancreas have been previously 
reported to be associated with an 
increased risk of developing 
extra-pancreatic tumours [1-
13].  Though some authors have 
reported an increased risk for 
gastric, lung, breast, kidney 
and thyroid cancers [13], the 
most frequent extra-pancreatic 
tumour consistently found in 
these patients has been colorectal 
cancer (CRC) [3, 6, 8, 9, 11, 13].
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ABSTRACT
Background & Aims: It has been reported that patients with intraductal papillary mucinous neoplasms of the 
pancreas are at an increased risk of colorectal cancer. The aim of our study was to investigate whether patients 
with intraductal papillary mucinous neoplasms are at a higher risk of colorectal adenomas with respect to the 
general population, as this condition represents the precursor of sporadic colorectal cancer. 
Methods: A case–control study was conducted at the Catholic University and University Sapienza, Rome, 
Italy. The cases were patients with intraductal papillary mucinous neoplasms without history of colorectal 
cancer, who had  underwent screening colonoscopy for the first time. The controls were individuals who had 
underwent first time colonoscopy for screening or evaluation of non-specific abdominal symptoms. Chi-square 
and Fisher tests were used to compare the distributions of categorical variables. 
Results: We enrolled 122 cases and 246 controls. Colorectal polyps were found in 52 cases (42.6%) and 79 
controls (32.1%) (p<0.05). In 29 cases (23.8%) and 57 controls (23.2%) histological examination disclosed 
adenomatous polyps (p=0.90). There was no difference between the groups in relation to the presence of polyps 
with low-grade (19.7% vs. 19.8%, p=0.98) and high-grade dysplasia (4.9% vs. 4.5%, p=0.85). 
Conclusion: Patients with intraductal papillary mucinous neoplasms of the pancreas are not  at  an increased 
risk for the development of adenomatous colorectal polyps. 
Key words: IPMN – colorectal cancer – colonoscopy – adenomatous polyps.
Abbreviations: BD-IPMN: branch duct intraductal papillary mucinous neoplasm; CRC: colorectal cancer; 
FAP: familiar adenomatous polyposis; FNA: fine needle aspiration; FOBT: fecal occult blood test; HNPCC: 
hereditary non-polyposis colorectal cancer; IPMN: intraductal papillary mucinous neoplasm; M-IPMN: mixed 
intraductal papillary mucinous neoplasm; MD-IPMNs: main duct intraductal papillary mucinous neoplasm; 




Colorectal cancer represents the third most common 
cancer worldwide with more than 1.3 million new cases 
(9.7% of total) and almost 700,000 deaths every year [14]. 
Almost 55% of the cases occur in more developed regions 
[14], where the prognosis is relatively favourable with a 5-year 
survival rate reaching 65% in USA, Canada, Australia and 
several European countries [15, 16]. On the other hand, the 
incidence is increasing in countries or areas with poor health-
care resources [17], where a 5-year survival is no more than 
50% [18]. Identification of all risk factors associated with CRC 
becomes of paramount importance to apply properly designed 
screening programs to those at higher risk than the general 
population in order to detect precancerous lesions or cancers 
at an early and more curable stage.
The mechanism(s) behind the association between IPMN 
and CRC is still unknown. It is well known that almost all 
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sporadic CRCs develop slowly over several years through the 
adenoma-carcinoma carcinogenetic sequence [19]. Thus, it is 
possible to hypothesize that the increased risk of colorectal CRC 
in IPMN patients may be related to an increased propensity to 
develop colorectal adenomas, which represent the precursors 
of sporadic CRC. Some authors have previously reported an 
increased prevalence of colorectal polyps in patients with 
IPMN, based on which they proposed to consider screening 
colonoscopy for all patients with IPMN [8]. This inference, 
however, has been based only on the result of this single study 
that was retrospective and based on a chart review, while no 
data coming from studies specifically designed to prospectively 
assess the rate of colonic polyps in IPMN patients are available.
To answer this important question, we conducted a two-
centre case-control study aimed at evaluating the prevalence of 
colorectal adenomas in consecutively enrolled Italian patients 
with IPMN undergoing first time screening colonoscopy as 
compared to matched controls.
MATERIAL AND METHODS
A two centre prospective case-control study was conducted 
at the Digestive Endoscopy Unit of the Catholic University 
and the Digestive and Liver Disease Unit of the University 
Sapienza, Rome, Italy between January 2012 and December 
2013. Detailed methodology has been previously described [13, 
20]. Cases were prevalent IPMN who had underwent screening 
colonoscopy for the first time in their life. The criteria for the 
IPMN diagnosis  were previously described [21]. The diagnosis 
of IPMN was considered as certain in the presence of either 
histological diagnosis obtained by endoscopic ultrasound (EUS) 
or surgical specimen, or cytologic diagnosis obtained by EUS. A 
highly probable diagnosis of IPMN was based on the presence 
of one or several main pancreatic duct and/or branch duct 
dilatation(s) and/or pancreatic cystic lesions communicating 
with pancreatic ducts at computed tomography (CT), magnetic 
resonance cholangiopancreatography with secretin stimulation 
(S-MRCP), endoscopic retrograde cholangiopancreatography 
(ERCP) or EUS. Patients were excluded if they had a history 
of CRC, if they had undergone a previous colonoscopy 
independently on the presence or absence of CRC and/
or colonic polyps, and if they had cystic lesions other than 
IPMN. Controls matched to each IPMN case (2:1) by gender 
and age (±5 years) were enrolled alongside among individuals 
who had underwent their first colonoscopy for screening 
or for evaluation of non-specific abdominal symptoms at 
both institutions. Individuals who underwent colonoscopy 
because of a personal history of CRC, of familiar adenomatous 
polyposis (FAP) or hereditary non-polyposis colorectal cancer 
(HNPCC), positivity to fecal occult blood test (FOBT), iron 
deficiency anaemia and bright red blood per rectum were 
excluded. Both cases and controls were interviewed by trained 
physicians using a structured questionnaire and data on 
demographics, lifestyle habits (alcohol consumption, cigarette 
smoking), prior medical history, cancer family history and 
medication use were collected.
Cases and controls underwent screening colonoscopy 
and the prevalence of colon polyps and/or CRC was 
determined. Polyethylene glycol lavage solution was used 
for colon preparation. Colonoscopies were conducted by 
experienced endoscopists from the Digestive Endoscopy 
Unit of the Catholic University (A.L., F.A.) and the Digestive 
and Liver Disease Unit of the University Sapienza (E.D.G.) 
Anatomical landmarks (Bauhin valve and appendix orifice) 
were recognized as proof that the entire colon had been 
examined. Patients who were diagnosed with CRC were 
referred to surgical evaluation, while all detected polyps were 
removed whenever possible. A histopathologic examination 
of all removed polyps was performed and histologic type of 
the polyp and the degree of dysplasia were determined. All 
colonoscopies were performed under conscious sedation 
(midazolam and phentanyl e.v.) and patients were observed in 
the recovery unit for 1 hour after the procedure. For those with 
positive colonoscopy findings, surveillance was suggested after 
proper treatment and histopathologic evaluation, according to 
current guidelines [22].
For IPMN cases data on IPMN characteristics, such as type 
of ductal involvement, focality, maximal dilation of the duct 
and presence of nodules or solid tissue inside the cyst cavity 
were collected. The type of duct involvement was determined 
by the revision of clinical imaging studies and/or based on 
endoscopic ultrasound (EUS) evaluation, and classified as 
either main duct (MD-IPMNs), branch duct (BD-IPMNs) or 
mixed (M-IPMNs).
We conducted a descriptive analysis using relative 
frequencies and percentages to summarize the characteristics 
of the IPMN patients at the time of diagnosis. Chi-square and 
Fisher exact tests were used to compare the distribution of 
categorical variables between patients with IPMNs and control 
subjects. Additionally, as we expected that the prevalence of 
colorectal polyps might differ between the compared groups 
based on the family history of CRC, we planned a priori to 
stratify our data according to the 1st-degree family history of 
CRC. Statistical analyses were performed using Stata software 
(StataCorp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP).
RESULTS
One hundred and twenty-two patients with IPMN and 
244 matched controls were prospectively enrolled in the 
study. Demography of the cases and characteristics of the 
IPMN lesions are reported in Table I. Patients with IPMN 
were predominantly female (61.5%), with an age over 60 
years in 69.6% of the cases. The large majority of the cases 
were branch duct (BD)-IPMN (87.7%) multifocal (67.2%) and 
without evidence of intra-lesional nodules (81.1%). The mean 
diameter of the largest lesions was 16.7±7.9mm, while the mean 
dilatation of the main pancreatic duct in main duct (MD)-
IPMN was 9.0±5.26mm (Table I). EUS±FNA was performed in 
80% of the IPMNs and overall they were treated conservatively 
with clinical follow up in 86.9% of the cases (Table I).
Table II reports demographics, lifestyle habits, previous 
medical history and cancer family history of IPMN cases and 
controls (Table II). Cases were significantly more likely to be 
drinkers (p<0.01) or to drink ≥21 drinks per week (p<0.05). 
They also had significantly more frequently a history of 
chronic pancreatitis (p<0.001), diabetes mellitus (p<0.001), 
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both insulin-dependent (p<0.001) and non-insulin dependent 
(p<0.05), as well as a previous history of cholecystectomy 
(p<0.01) (Table II). With regard to cancer family history, 
IPMN patients were significantly more likely to have 2nd-
degree family history for any cancer (p<0.05), and 2nd-degree 
family history for pancreatic ductal adenocarcinoma (PDAC) 
(p<0.05). On the other hand, controls were significantly more 
likely to have a 1st-degree relative with a history of CRC 
(p<0.001).
In all cases and controls the entire colon was examined. 
Colorectal polyps were found in 52 IPMNs (42.6%) and in 
79 controls (32.1%) (p<0.05) (Table II). Mean polyp diameter 
was 6.1±5.28mm. In 29 cases (23.8%) and 57 controls (23.2%) 
histologic examination disclosed adenomatous polyps, which 
were multiple in 11 cases (9%) and 20 controls (8.1%) (Table 
II). There was no difference between the groups also in regard 
to presence of polyps with low-grade dysplasia or high-grade 
dysplasia (Table II). Three cases of CRC were detected, 2 in 
IPMNs (1.6%) and 1 in the controls (0.4%), but the frequency 
was too small to make any comparison between the groups. 
As we expected that 1st-degree family history of CRC might 
affect the prevalence of colorectal polyps, Table III reports the 
data stratified according to this covariate. No difference in the 
prevalence of colorectal polyps or adenomatous polyps with 
low-grade or high-grade dysplasia between IPMN cases and 
controls among those with 1st-degree family history of CRC 
was observed. A slightly higher prevalence of colorectal polyps 
among cases than controls without 1st-degree family history 
of CRC was reported (43.3% vs. 31.4%, p=0.051) (Table III). 
However, when restricting the analysis to adenomatous polyps, 
no difference between IPMN cases and controls without 1st-
degree family history of CRC was observed (Table III). 
DISCUSSION
We conducted a case-control study in order to evaluate the 
prevalence of colorectal adenomas in prospectively enrolled 
Italian patients with IPMN undergoing first time screening 
colonoscopy. Compared to a matched control population of 
individuals who underwent colonoscopy for screening or for 
evaluation of non-specific abdominal symptoms, no increased 
prevalence of adenomatous polyps was found in IPMN 
patients. This result did not show an increased propensity to 
develop colorectal adenomas among IPMN patients.
Colorectal carcinoma has been the most frequent extra-
pancreatic tumour consistently found in IPMN patients 
[3, 6, 13]. Eguchi et al. [3] reported that IPMN is a strong 
independent risk factor for preoperative CRC. They found that 
CRC occurred 5.37 times more frequently in IPMN patients 
than in the general population [3]. Rial et al. [6] reported 
1.66 times higher rate of CRC in patients with invasive IPMN 
as compared to US general population and our study group 
previously reported that IPMN patients in Italy harbour 
CRC 2.26 times more frequently than expected [13]. The 
mechanism(s) for the association between IPMN and CRC 
has not been elucidated so far. One important point has been 
raised by Reid-Lombardo et al. [8], who performed a large 
case-control retrospective study at the Mayo Clinic. They 
found adenomatous colorectal polyps to be present 2 and 1.4 
times more frequently in patients with IPMN as compared to 
patients with pancreatic adenocarcinoma and to the general 
population, respectively. These findings prompted the authors 
to advocate screening colonoscopy for all patients with IPMN. 
The adenoma-carcinoma sequence is a well-known 
carcinogenetic mechanism that is responsible for almost 
all sporadic CRCs [19]. Colorectal cancer develops from 
the progressive transformation of adenomatous polyps [19] 
through a series of molecular events including APC gene 
mutation [23], as well as KRAS and TP53 inactivation [24]. 
Based on this very well-known mechanism and the results of 
the study by Reid-Lombardo et al. [8], we performed a study 
to test the hypothesis that the risk of CRC development in 
patients with IPMN could be related to an increased propensity 
to harbour colorectal adenomas.
Contrary to the study by Reid-Lombardo et al. [8] that 
was based on a retrospective chart review with possible bias 
toward an increased prevalence of adenomatous polyps in cases 
because of an increased probability of undergoing diagnostic 
tests including colonoscopy, we evaluated the prevalence of 
colorectal polyps among a large cohort of consecutively enrolled 
patients with IPMN undergoing first time colonoscopy. As 
compared with a matched control population also undergoing 
Table I. Clinical features of the 122 patients with intraductal papillary 
mucinous neoplasms of the pancreas at the time of diagnosis
Number %
Gender
    Male 47 38.5%
    Female 75 61.5%
Age (years)
    <50 15 12.3%
    50-59 22 18.0%
    60-69 43 35.2%
    ≥70 42 34.4%
Duct involvement
    BD-IPMN 107 87.7%
    MD-IPMN 7 5.7%
    C-IPMN 8 6.6%
Focality
    Unifocal 40 32.8%
    Multifocal 82 67.2%
Branch duct maximum dilatation (mm) (§) 16.69 12.0-21.0
Wirsung maximal dilatation (mm) (§) 9.0 5.0-10
Nodules
    No 99 81.1%
    Yes 23 18.9%
Surgery
    No 106 86.9%
    Yes 16 13.1%
Endosonography
    No 27 22.1%
    Yes 95 77.9%
(§) Median and interquartile range; IPMN, intraductal papillary 
mucinous neoplasm; BD, branch duct; MD, main duct; C, combined
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first time colonoscopy for screening purposes or to evaluate 
non-specific symptoms, we found a higher prevalence of 
colorectal polyps among IPMN patients. When considering 
adenomatous polyps only, however, this difference was no 
longer significant. Furthermore, these results were confirmed 
after stratifying according to the 1st-degree family history of 
CRC, which might affect the presence of colorectal adenomas. 
Therefore our study did not confirm the findings of Reid-
Lombardo et al. [8]. However, when interpreting our results, 
Table II. Characteristics of patients with intraductal papillary mucinous neoplasms of the pancreas and 
controls by selected variables of family history chronic conditions, medication and lifestyles, and polyp 
findings according to colonoscopy
Cases (n=122) Controls (n=246) p value
Male sex 47 38.5% 94 38.2% 0.95
Age 63,4 ±11.3 62,3 ±10.9 0.25
Cigarette smoking 
Ever 64 53.8% 115 46.7% 0.21
≥20 pack-years 33 28.2% 48 19.5% 0.06
Alcohol 
Ever 53 44.5% 75 30.5% <0.01
≥21 drinks per week 10 9.0% 7 2.9% <0.05
Medical history
History of chronic pancreatitis 8 6.7% 0 0.0% <0.001
History of diabetes 23 19.3% 18 7.3% <0.001
  History of insulin-dependent diabetes 6 5.0% 0 0.0% <0.001
  History of noninsulin-dependent diabetes 17 14.3% 16 6.7% <0.05
History of peptic ulcer 4 3.3% 3 1.2% 0.23
History of cholecystectomy 20 16.7% 17 6.9% <0.01
Cancer family history
Any cancer (1st degree) 70 57.9% 134 57.8% 0.99
Any cancer (2nd degree) 22 18.2% 24 10.3% <0.05
PDAC (1st degree) 12 9.9% 13 5.3% 0.10
PDAC (2nd degree) 4 3.3% 0 0.0% <0.05
Common sites, first-degree family history
Colorectal cancer 17 14.1% 93 37.8% <0.001
Gastric cancer 9 7.4% 12 4.9% 0.32
Breast cancer 6 5.0% 21 8.5% 0.22
Lung cancer 12 9.9% 18 7.3% 0.39
Uterine cancer 3 2.5% 4 1.6% 0.69
Melanoma 3 2.5% 3 1.2% 0.40
Hepatocellular carcinoma 6 5.0% 5 2.0% 0.19
Use of drugs
Aspirin 16 13.2% 34 14.3% 0.78
Statins 20 16.5% 49 20.6% 0.36
Insulin 7 5.8% 0 0.0% <0.001
Colon polyps 52 42.6% 79 32.1% <0.05
Adenomatous polyps 29 23.8% 57 23.2% 0.9
Multiple adenomatous polyps 11 9.0% 20 8.1% 0.77
Low grade dysplasia 24 19.7% 48 19.5% 0.98
 High grade dysplasia 6 4.9% 11 4.5% 0.85
Data are mean (SD) for continuous variables or number of individuals (%) for discrete variables; PDAC, 
pancreatic ductal adenocarcinoma
it should be kept in mind that the above mentioned study 
included more MD-IPMNs and C-IPMNs. It could be a case 
that patients harbouring these more invasive IPMN types are 
more prone to develop colorectal adenomas.
Overall, the results of our study suggest that factors other 
than an increased propensity of IPMN patients to harbour 
colorectal adenomas could be responsible for the increased 
occurrence of CRC in these patients. It could be hypothesised 
that the mechanism for an increased risk of CRC in IPMN 
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might be an accelerated adenomas formation, as seen in 
patients with HNPCC. However, two prospective studies have 
been published recently [25, 26]. They reported no increased 
risk among IPMN patients for all incident extrapancreatic 
malignancies, including CRC.  As these are so far the largest 
available prospective data on IPMN and CRC, it could be 
that the reason we could not detect any increased risk for 
adenomatous polyps in IPMN patients depicts a lack of 
significant association between IPMN and CRC.
We observed several risk factors associated with IPMN. 
History of diabetes, use of insulin and history of chronic 
pancreatitis has been previously reported to be associated with 
IPMN [20]. We found an association between cholecystectomy 
and IPMN, which has never been reported before and the 
meaning of which appears unclear.
We acknowledge that our study has some limitations. 
It included a relatively limited number of IPMN cases, and 
because of the small number of CRCs detected, it was unable 
to detect a difference in the CRC occurrence as compared to 
matched controls. However, the study was designed to assess 
the prevalence of adenomas and not of CRC in the IPMN 
group. Furthermore, a significantly higher rate of chronic 
pancreatitis and heavy drinking in the IPMN group suggests 
misclassification indicating that some of the cystic lesions 
may be pseudocysts rather than IPMNs. However, this is the 
first study assessing the prevalence of colorectal adenomas in 
IPMN patients at a first time colonoscopy. Although the results 
reported were against our prior hypothesis of a higher prevalence 
of colorectal adenomas among IPMN patients than in the control 
population, our study highlighted the need to further explore 
the issue of association between IPMN and CRC.
CONCLUSION
Patients wiht IPMN are not at an increased risk for 
development of adenomatous colorectal polyps. Further 
research is  required in order to assess if there is actually a real 
association between IPMN and CRC. 
Conflicts of interest: None declared.
Table III. Prevalence of colon polyps in intraductal papillary mucinous neoplasms of the 
pancreas cases and controls according to family history of colorectal cancer 
1st-degree family history of CRC Cases (n=104) Controls (n=153) p-value
Colon polyps 45 43.4% 48 31.4% 0.051
Adenomatous polyps 26 25.0% 36 23.5% 0.79
Multiple adenomatous polyps 10 9.6% 13 8.5% 0.76
Low grade dysplasia 21 20.2% 30 19.6% 0.90
High grade dysplasia 8 7.7% 8 5.2% 0.88
No 1st-degree family history of CRC Cases (n=17) Controls (n=93) p-value
Colon polyps 6 35.3% 31 33.3% 0.85
Adenomatous polyps 3 17.7% 21 22.6% 0.65
Multiple adenomatous polyps 1 5.9% 7 7.5% 0.81
Low grade dysplasia 3 17.6% 18 19.3% 0.85
 High grade dysplasia 1 5.9% 3 3.2% 0.59
Data are number of individuals (%); CRC, colorectal cancer
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